Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $1,268,800.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert sold 20,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Chad Gassert also recently made the following trade(s):

• On Monday, June 3rd, Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.41, for a total value of $1,288,200.00.
• On Wednesday, May 1st, Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.62, for a total value of $1,332,400.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $60.82 on Friday. The stock has a 50 day moving average price of $63.93 and a 200 day moving average price of $61.95. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95. The stock has a market capitalization of $1.28 billion, a PE ratio of 38.01 and a beta of 0.75.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The company had revenue of $137.43 million during the quarter, compared to analysts’ expectations of $125.01 million. Analysts predict that ANI Pharmaceuticals, Inc. will post 3.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ANIP shares. Guggenheim reiterated a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright increased their price objective on ANI Pharmaceuticals from $87.00 to $94.00 and gave the stock a “buy” rating in a report on Wednesday, June 26th. Finally, Capital One Financial assumed coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $82.75.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ANIP. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after buying an additional 277,989 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 5.4% in the third quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock valued at $65,746,000 after buying an additional 58,204 shares during the last quarter. Global Alpha Capital Management Ltd. lifted its holdings in ANI Pharmaceuticals by 10.8% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after purchasing an additional 56,900 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $3,007,000. Finally, Assenagon Asset Management S.A. lifted its holdings in ANI Pharmaceuticals by 121.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 83,944 shares of the specialty pharmaceutical company’s stock worth $5,803,000 after purchasing an additional 46,008 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.